UA104590C2 - Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона - Google Patents

Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона

Info

Publication number
UA104590C2
UA104590C2 UAA201100098A UAA201100098A UA104590C2 UA 104590 C2 UA104590 C2 UA 104590C2 UA A201100098 A UAA201100098 A UA A201100098A UA A201100098 A UAA201100098 A UA A201100098A UA 104590 C2 UA104590 C2 UA 104590C2
Authority
UA
Ukraine
Prior art keywords
suspension formulation
dosage form
pharmaceutical dosage
capsule
capsule pharmaceutical
Prior art date
Application number
UAA201100098A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роман Мессершмид
Рудольф Биндер
Томас БОК
Вернер Брокс
Original Assignee
Берингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40911908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104590(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берингер Ингельхайм Интернациональ Гмбх filed Critical Берингер Ингельхайм Интернациональ Гмбх
Publication of UA104590C2 publication Critical patent/UA104590C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение касается композиции активного соединения моноэтансульфоната 3-Z-[1-(4-(N-((4-метилпиперазин-1-ил)метилкарбонил)-N-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона, которая представляет собой вяжущую липидную суспензию активного соединения в триглицеридах со средней длиной цепи, твердом жире и лецитине.
UAA201100098A 2008-06-06 2009-06-04 Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона UA104590C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08157748 2008-06-06
PCT/EP2009/056878 WO2009147212A1 (en) 2008-06-06 2009-06-04 Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative

Publications (1)

Publication Number Publication Date
UA104590C2 true UA104590C2 (ru) 2014-02-25

Family

ID=40911908

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201100098A UA104590C2 (ru) 2008-06-06 2009-06-04 Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона

Country Status (35)

Country Link
US (4) US20110301177A1 (ru)
EP (1) EP2299987B1 (ru)
JP (2) JP5661031B2 (ru)
KR (2) KR101725469B1 (ru)
CN (2) CN102056598B (ru)
AR (1) AR072059A1 (ru)
AU (1) AU2009254548B2 (ru)
BR (1) BRPI0913434B8 (ru)
CA (1) CA2726267C (ru)
CL (1) CL2010001279A1 (ru)
CO (1) CO6280467A2 (ru)
CY (1) CY1120533T1 (ru)
DK (1) DK2299987T3 (ru)
EA (1) EA029996B1 (ru)
EC (1) ECSP10010660A (ru)
ES (1) ES2669469T3 (ru)
HR (1) HRP20180709T1 (ru)
HU (1) HUE039187T2 (ru)
IL (1) IL208954A (ru)
LT (1) LT2299987T (ru)
MA (1) MA32385B1 (ru)
MX (2) MX359229B (ru)
MY (1) MY158930A (ru)
NO (1) NO2299987T3 (ru)
NZ (1) NZ603162A (ru)
PE (1) PE20100254A1 (ru)
PL (1) PL2299987T3 (ru)
PT (1) PT2299987T (ru)
RS (1) RS57142B1 (ru)
SI (1) SI2299987T1 (ru)
TW (1) TW201002691A (ru)
UA (1) UA104590C2 (ru)
UY (1) UY31879A (ru)
WO (1) WO2009147212A1 (ru)
ZA (1) ZA201007636B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
US20170065529A1 (en) 2015-09-09 2017-03-09 Boehringer Ingelheim International Gmbh Pharmaceutical dosage form for immediate release of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN103037851A (zh) * 2010-06-02 2013-04-10 安斯泰来德国有限公司 苯达莫司汀的口服剂型
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
BR112015006363A2 (pt) 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20150209360A1 (en) * 2014-01-30 2015-07-30 Orbz, Llc Oral caffeine delivery composition
CN114504562A (zh) * 2015-03-13 2022-05-17 江苏豪森药业集团有限公司 含有吲哚满酮衍生物混悬液的胶囊制剂及其制备方法
ES2971096T3 (es) 2015-06-06 2024-06-03 Cloudbreak Therapeutics Llc Composiciones y métodos para tratar el terigio
CN107019697A (zh) * 2016-02-02 2017-08-08 瑞阳(苏州)生物科技有限公司 预防或治疗纤维化疾病的药物组合物及其应用
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
US10561630B2 (en) * 2016-10-25 2020-02-18 Glykon Technologies Group, Llc Hydroxycitric acid compounds and capsule liquid delivery
CN108066343A (zh) * 2016-11-08 2018-05-25 瑞阳(苏州)生物科技有限公司 一种预防或治疗肾纤维化疾病的药物
JP2019536812A (ja) 2016-12-12 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ
WO2018177893A1 (en) 2017-03-28 2018-10-04 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of muscular dystrophy
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
HRP20251042T1 (hr) 2017-10-23 2025-10-24 Boehringer Ingelheim International Gmbh Nova kombinacija aktivnih sredstava za liječenje progresivnih intersticijskih bolesti pluća s fibroznim promjenama (pf-ild)
WO2019106692A1 (en) * 2017-11-29 2019-06-06 Sun Pharmaceutical Industries Limited Oral suspension of nintedanib esylate
LT3761980T (lt) 2018-03-07 2024-03-12 Pliant Therapeutics, Inc. Aminorūgščių junginiai ir jų panaudojimo būdai
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
US12303504B2 (en) * 2018-09-13 2025-05-20 Oncosol Limited Non-aqueous chemotherapeutic suspensions for oral dosage
AU2019363244B2 (en) * 2018-10-15 2024-10-03 Cipla Limited Pharmaceutical formulation
CN112386580B (zh) * 2019-08-13 2022-07-08 齐鲁制药有限公司 具有改善的溶出度和稳定性的尼达尼布药物制剂、制备方法及其应用
CN114761001A (zh) 2019-12-04 2022-07-15 爱杜西亚药品有限公司 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合
JP2023519600A (ja) 2020-04-01 2023-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 線維性状態の治療におけるバイオマーカーの使用
EP4098246A1 (en) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation of nintedanib
EP4416147A1 (en) * 2021-10-14 2024-08-21 Pliant Therapeutics, Inc. Integrin inhibitors and uses thereof in combination with other agents
CN114404382B (zh) * 2022-01-24 2023-05-12 南京康川济医药科技有限公司 乙磺酸尼达尼布软胶囊及其制备方法
JP2025506869A (ja) 2022-02-28 2025-03-13 ナフォーミックス テクノロジーズ リミテッド 特発性肺線維症の処置のための組成物及び方法
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use
US20250248971A1 (en) * 2024-02-05 2025-08-07 Anxo Pharmaceutical Co., Ltd. Pharmaceutical composition and method using the same
WO2025254255A1 (ko) 2024-06-05 2025-12-11 영진약품 주식회사 닌테다닙 또는 이의 약학적으로 허용가능한 염을 포함하는 개선된 용출률을 갖는 신규한 정제 및 이의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3579384D1 (de) 1984-07-24 1990-10-04 Scherer Gmbh R P Oxytetracyclin-hc1-weichgelatinekapseln und verfahren zu ihrer herstellung.
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
DE19603402A1 (de) 1995-02-24 1996-08-29 Basf Ag Weichgelatinekapseln
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
IL158390A0 (en) * 2001-05-01 2004-05-12 Pfizer Prod Inc Method for manufacturing a low dose pharmaceutical composition
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060293260A1 (en) * 2005-05-24 2006-12-28 Wyeth Useful high load concentrate compositions for control of ecto-and endo-parasites
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
MY158929A (en) 2008-06-06 2016-11-30 Boehringer Ingelheim Int Pharmaceutical combination
EP2299987B1 (en) 2008-06-06 2018-02-21 Boehringer Ingelheim International GmbH Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
UA107560C2 (uk) * 2008-06-06 2015-01-26 Фармацевтична лікарська форма для негайного вивільнення похідної індолінону
WO2010081817A1 (en) * 2009-01-14 2010-07-22 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
EP2647375A1 (en) 2009-05-14 2013-10-09 Boehringer Ingelheim International Gmbh Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases

Also Published As

Publication number Publication date
PE20100254A1 (es) 2010-04-21
MX359229B (es) 2018-09-20
MA32385B1 (fr) 2011-06-01
TW201002691A (en) 2010-01-16
EA029996B1 (ru) 2018-06-29
NO2299987T3 (ru) 2018-07-21
JP5905542B2 (ja) 2016-04-20
CN102056598B (zh) 2017-09-19
PL2299987T3 (pl) 2018-08-31
MY158930A (en) 2016-11-30
SI2299987T1 (en) 2018-06-29
JP2014208712A (ja) 2014-11-06
CO6280467A2 (es) 2011-05-20
KR20110017872A (ko) 2011-02-22
ZA201007636B (en) 2011-08-31
US20160324791A1 (en) 2016-11-10
AU2009254548A1 (en) 2009-12-10
US20110301177A1 (en) 2011-12-08
ECSP10010660A (es) 2011-02-28
US20140004187A1 (en) 2014-01-02
PT2299987T (pt) 2018-05-21
BRPI0913434B8 (pt) 2021-05-25
WO2009147212A1 (en) 2009-12-10
EP2299987B1 (en) 2018-02-21
CN105193720A (zh) 2015-12-30
CN102056598A (zh) 2011-05-11
ES2669469T3 (es) 2018-05-25
EP2299987A1 (en) 2011-03-30
KR101725469B1 (ko) 2017-04-11
JP5661031B2 (ja) 2015-01-28
RS57142B1 (sr) 2018-07-31
LT2299987T (lt) 2018-05-25
JP2011522812A (ja) 2011-08-04
CA2726267A1 (en) 2009-12-10
CA2726267C (en) 2017-10-31
BRPI0913434A2 (pt) 2015-12-01
CY1120533T1 (el) 2019-07-10
US20160022672A1 (en) 2016-01-28
HRP20180709T1 (hr) 2018-06-15
BRPI0913434B1 (pt) 2020-10-13
HUE039187T2 (hu) 2018-12-28
AU2009254548B2 (en) 2015-10-01
IL208954A (en) 2017-11-30
MX2010013203A (es) 2011-02-25
AR072059A1 (es) 2010-08-04
CN105193720B (zh) 2018-07-31
CL2010001279A1 (es) 2011-05-13
IL208954A0 (en) 2011-01-31
EA201001856A1 (ru) 2011-06-30
KR20170020557A (ko) 2017-02-22
NZ603162A (en) 2014-05-30
DK2299987T3 (en) 2018-05-22
UY31879A (es) 2010-01-29
US9907756B2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
MX359229B (es) Forma de dosificación farmacéutica en cápsula que comprende una formulación en suspensión de un derivado de indolinona.
MX338001B (es) Forma de dosificacion farmaceutica para la liberacion inmediata de un derivado de indolinona.
MY149731A (en) Compounds
UA94988C2 (ru) Способ получения производной бензимидазола и промежуточное соединение
MX2007001099A (es) Procedimiento para preparar un producto de microcapsula de alta estabilidad y metodo para uso del mismo.
MY163216A (en) Compositions and methods for modulating fxr
TN2014000427A1 (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MX2012006022A (es) Compuestos novedosos como moduladores de receptor con utilidad terapeutica.
CA2818986A1 (en) Indole derivatives as modulators of s1p receptors
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
TW200616952A (en) Novel crystal form of (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride
WO2009071691A3 (de) Oxindol-derivate und ihre verwendung als medikament
MX336578B (es) Derivados de n-(imidazolidin-2-ilideno)-heterociclopenta[b] pirididina como moduladores de receptores de alfa 2 adrenergicos.
TN2010000558A1 (en) Capsule pharmaceutical doage form comprising a suspension formulation of an indolinone derivative
TN2010000555A1 (en) Pharmaceutical dosage form for immediate release of an indolinone derivative
TH115893A (th) รูปแบบขนาดยาทางเภสัชกรรมชนิดแคปซูลซึ่งประกอบรวมด้วยสูตรผสมสารแขวนลอยของอนุพันธ์อินโดลิโนน
PL388789A1 (pl) Kompozycja farmaceutyczna zawierajaca rosuwastatynę, sposób jej wytwarzania oraz postacie leku zawierające tę kompozycję